NewAmsterdam Pharma Co NV
NAMSHealthcare|Biotechnology|Netherlands
$35.30
-0.66 (-1.84%)
Tangible Book
$5.70
About
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Stock Price
+60.3%(1Y)
Pipeline Summary
20 total trials6
Phase 1
7
Phase 2
6
Phase 3
0
Phase 4
Completed: 13Recruiting: 4Active: 3
Active Trials (7)
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NCT07219602Lipidemia
Phase 3Recruiting
Enrollment: 300 participants
Impact of the Corrie Lipids Digital Health Program on Lipid Optimization
NCT07478887Cardiovascular Risk
N/ARecruiting
Enrollment: 1,000 participants
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
NCT05202509Atherosclerotic Cardiovascular Disease
Phase 3Active
Enrollment: 9,541 participants
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
NCT06496243Dyslipidemias
Phase 2Recruiting
Enrollment: 69 participants
Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
NCT05972278Lipid Metabolism
Phase 1Active
Enrollment: 22 participants
BioScore
6.3/10
Watchlist
Ownership
Recent Insider Trades
Kooij Louise FrederikaSELL
2026-06-2240,000 shares @ $30.2
Kooij Louise FrederikaSELL
2026-05-2665,000 shares @ $35.69
LANGE LOUIS GSELL
2026-03-1144,619 shares @ $30.42
Kastelein Johannes Jacob PieterSELL
2026-03-09300,000 shares @ $30.3
LANGE LOUIS GSELL
2026-03-0628,186 shares @ $29.41
Recent News
2026-06-30 16:03:55
Data last updated: Jul 13, 2026, 12:40 PM